Table 1 Baseline characteristics of AS patients and controls (combined group 40–89 years)
From: Malignancy in ankylosing spondylitis: a cross-sectional analysis of a large population database
Study group | Total AS N = | Missing N (%) | AS patients w/cancer N (%) | AS patients w/o cancer N (%) | Total control N = | Missing N (%) | Control w/cancer N (%) | Control w/o cancer N (%) |
|---|---|---|---|---|---|---|---|---|
# of patients | 10,940 | 1410 (12.9) | 9530 (87.1) | 13,344,160 | 2,055,530 (15.4) | 11,288,630 (84.6) | ||
Male | 5180 | 760 (53.9) | 4420 (46.4) | 6,140,340 | 1,012,290 (49.2) | 5,128,050 (45.4) | ||
Female | 5760 | 650 (46.1) | 5110 (53.6) | 7,214,190 | 1,044,170 (50.8) | 6,170,020 (54.6) | ||
White | 8900 | 1210 (85.8) | 7690 (80.7) | 9,617,790 | 1,678,310 (81.7) | 7,939,480 (70.3) | ||
Black | 940 | 90 (6.4) | 850 (8.9) | 1,321,400 | 169,780 (8.3) | 1,151,620 (10.2) | ||
Other races | 1100 [10] | 2,404,970 (18) | ||||||
Active Smoker | 2790 | 3280 (29.9) | 430 (30.5) | 2360 (24.8) | 2,358,780 | 7,255,250 (54.4) | 436,780 (21.3) | 1,922,000 (17.0) |
Ex smoker | 3630 | 650 (46.1) | 2980 (31.3) | 2,855,190 | 703,690 (34.2) | 2,151,500 (19.1) | ||
Never smoker | 1240 | 250 (17.7) | 990 (10.4) | 874,940 | 209,000 (10.2) | 665,940 (5.9) | ||
TNFi | 4300 | 530 (37.6) | 3770 (39.6) | 39,100 | 6110 (0.3) | 32,990 (0.3) | ||
IL-17i | 490 | 60 (4.3) | 430 (4.5) | 2950 | 440 (0.02) | 2510 (0.02) | ||
IBD | 560 | 120 (8.5) | 440 (4.6) | 115,990 | 27,990 (1.4) | 88,000 (0.8) | ||
Uveitis | 1390 | 210 (14.9) | 1180 (12.4) | 45,270 | 9970 (0.5) | 3530 (0.03) | ||
Psoriasis | 1780 | 200 (14.2) | 1580 (16.6) | 185,260 | 40,110 (1.95) | 145,150 (1.3) |